Bright Minds Biosciences (NASDAQ:DRUG) Now Covered by Analysts at Piper Sandler

Piper Sandler assumed coverage on shares of Bright Minds Biosciences (NASDAQ:DRUG - Free Report) in a report published on Thursday, Marketbeat Ratings reports. The firm issued an overweight rating and a $93.00 price objective on the stock.

DRUG has been the topic of a number of other reports. HC Wainwright initiated coverage on shares of Bright Minds Biosciences in a report on Friday, January 10th. They issued a "buy" rating and a $85.00 price target on the stock. Baird R W upgraded Bright Minds Biosciences to a "strong-buy" rating in a research report on Monday, November 25th. Robert W. Baird started coverage on Bright Minds Biosciences in a research note on Monday, November 25th. They set an "outperform" rating and a $75.00 price target for the company. Finally, Cantor Fitzgerald started coverage on Bright Minds Biosciences in a research note on Friday, January 10th. They issued an "overweight" rating on the stock. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Bright Minds Biosciences currently has an average rating of "Buy" and a consensus target price of $84.33.

Bright Minds Biosciences Price Performance

Shares of NASDAQ DRUG traded down $1.53 during mid-day trading on Thursday, reaching $31.83. The company's stock had a trading volume of 265,279 shares, compared to its average volume of 96,473. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.31 and a quick ratio of 11.31. Bright Minds Biosciences has a 52 week low of $0.93 and a 52 week high of $79.02. The stock has a fifty day moving average of $38.57 and a two-hundred day moving average of $21.00. The firm has a market capitalization of $140.98 million, a PE ratio of -63.65 and a beta of -6.52.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last posted its quarterly earnings results on Monday, December 30th. The company reported ($0.12) EPS for the quarter. As a group, sell-side analysts anticipate that Bright Minds Biosciences will post -2.58 EPS for the current fiscal year.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.